NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Pluri Inc. (PLUR) Stock Analysis

Pluri Inc. (PLUR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PLUR

$1.36

−$0.01 (−0.73%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLUR with… →

PLUR Key Statistics

As of Sep 4, 2026
Trading
Open
$1.41
Previous Close
$1.37
Day's Range
1.31–1.45
52-Week Range
1.25–5.17
Volume
15.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.67
Valuation
Market Cap
$16.31M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
15.11
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.08
Financials (FY)
Revenue (FY)
$1.34M+309.82%
Net Income (FY)
−$22.58M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.99M
1-Year Return
−71.96%
Dividend and dates
Avg Volume
29.59K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PLUR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−54.52%
2025−30.14%
2024−7.76%
2023−38.30%
2022−35.62%
2021−79.35%
2020+79.44%
2019−50.13%
2018−42.75%
2017−3.50%
2016 (partial year)−6.54%

As of September 4, 2026.

PLUR Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$1.34M−$22.58M−1690.3%
2024$326.00K−$20.89M−6407.4%
2023$287.00K−$28.32M−9867.9%
2022$234.00K−$41.24M−17624.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.34M$654.00K−$22.18M−$22.58M−1690.3%
2024$326.00K$322.00K−$22.16M−$20.89M−6407.4%
2023$287.00K$278.00K−$27.25M−$28.32M−9867.9%
2022$234.00K$234.00K−$41.59M−$41.24M−17624.8%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

PLUR Valuation vs Biotechnology Median

Median of 656 stocks
MetricPLURBiotechnology medianvs median
P/S ratio15.1115.261% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Pluri Inc. (PLUR) at $16.31M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 127 employees.

Over the past 52 weeks the price has ranged from $1.25 to $5.17. PLUR last closed at $1.36 on September 4, 2026. That is −$0.01 (−0.73%) against the previous close. The latest close sits 8.8% above that 52-week low.

Financial Health

In fiscal 2025, Pluri Inc. reported revenue of $1.34M. Against the prior fiscal year total of $326.00K, that is a change of +309.82%. The same year closed with a net loss of $22.58M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.08.

Across the 4 fiscal years on file, revenue moves from $234.00K in 2022 to $1.34M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 15.11 times revenue. On price-to-sales that is 0.99% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.67. Annualized volatility over the trailing 10 years is 73.86%. The trailing one-year price return is −71.96%. Across 10 years the annualized return works out at −36.72%.

Growth & Income

The record shows no dividend for PLUR.

The strongest complete calendar year on file is 2020 at +79.44%; the weakest is 2021 at −79.35%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is −54.52%.

Peer Comparison

Pluri Inc. (PLUR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pluri Inc. PLUR $16.31M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Pluri Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pluri Inc.

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Visit website →